Skip to Content

Agrylin (anagrelide) Disease Interactions

There are 4 disease interactions with Agrylin (anagrelide):

Major

Anagrelide (Includes Agrylin) ↔ Cardiac Disease

Severe Potential Hazard, High plausibility

Applies to: Cardiovascular Disease

The use of anagrelide may produce a positive inotropic effect, vasodilation, tachycardia, palpitations, and congestive heart failure. Therapy with anagrelide should be administered cautiously in patients with cardiac disease. A cardiovascular examination is recommended prior to beginning therapy with anagrelide.

References

  1. "Product Information. Agrylin (anagrelide)." Roberts Pharmaceutical Corporation, Eatontown, NJ.
Major

Anagrelide (Includes Agrylin) ↔ Liver Disease

Severe Potential Hazard, High plausibility

Applies to: Liver Disease

Anagrelide undergoes extensive metabolism in the liver, with less than 1% recovered unchanged in the urine. Therapy with anagrelide should be administered cautiously in patients with liver disease (bilirubin, SGOT, or other liver measurements greater than 1.5 times normal) and only when the benefits outweigh the risks. Monitoring for signs of liver toxicity is recommended.

References

  1. "Product Information. Agrylin (anagrelide)." Roberts Pharmaceutical Corporation, Eatontown, NJ.
Major

Anagrelide (Includes Agrylin) ↔ Renal Dysfunction

Severe Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

The use of anagrelide has been rarely associated with renal failure most often in patients with serum creatinine values greater than 2.0. Therapy with anagrelide should be administered cautiously in patients with renal dysfunction. Monitoring for signs of renal toxicity is recommended in these patients.

References

  1. "Product Information. Agrylin (anagrelide)." Roberts Pharmaceutical Corporation, Eatontown, NJ.
Moderate

Anagrelide (Includes Agrylin) ↔ Pulmonary Dysfunction

Moderate Potential Hazard, Moderate plausibility

Applies to: Pulmonary Impairment

The use of anagrelide may cause interstitial lung diseases, including allergic alveolitis, eosinophilic pneumonia, and interstitial pneumonitis. The symptoms may present as progressive dyspnea with lung infiltrations. Close monitoring should be exercised when using this agent in patients with pulmonary dysfunction. It is recommended to discontinue anagrelide and evaluate the patient if symptoms of pulmonary toxicity occur.

Agrylin (anagrelide) drug Interactions

There are 594 drug interactions with Agrylin (anagrelide)

Agrylin (anagrelide) alcohol/food Interactions

There is 1 alcohol/food interaction with Agrylin (anagrelide)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide